living.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Long and strong, as Buffet says: "The stock market is designed to transfer money from the active to the patient."
Holding Long and strong still. DD never lies..
Bear raid IMO... we will see.
LBSR short info:
http://regsho.finra.org/FORFshvol20110128.txt
http://regsho.finra.org/FORFshvol20110201.txt
Date |ticker|short|total volume
20110128|LBSR|58400|652692
20110201|LBSR|1417317|7716248
LBSR BEAR RAID today.... love it.
Not sure what is going on here, bear raid @ its finest imo.
Thanks for the cheapies, keep um coming.
Which one was it? This is getting fun!
MMTE .0021!!! getting thin!
That is very good news IMO, will we break it?
PRECIOUS METALS: Gold Rises Slightly After Data Disappoint 01/27 08:29 AM
NEW YORK (Dow Jones)--Gold futures rose slightly Thursday as weaker-than- forecast U.S. durable goods orders and jobless claims boosted expectations monetary policy will remain easy for longer.
The most actively traded gold contract, for February delivery, was recently up $2.30, or 0.2%, at $1,335.30 a troy ounce on the Comex division of the New York Mercantile Exchange.
"The prospect of low rates being continued here is why (gold) rebounded," said MF Global analyst Tom Pawlicki.
Gold jumped after data showed U.S. demand for long-lasting goods unexpected fell last month, as manufacturers' orders for durable goods decreased 2.5% when economists had predicted a 1.4% gain.
Separate figures showed the number of U.S. workers filing new claims for unemployment benefits unexpectedly surged last week. Initial jobless claims rose 51,000 to 454,000 in the week ended Jan. 22. Economists had expected claims would rise by just 1,000.
The disappointing data reinforced the notion the Federal Reserve will stick to its easy-money policy of ultralow interest rates and Treasury purchases that has helped send gold to record highs in recent weeks.
Federal Reserve officials this week, at their first policy-setting meeting of 2011, voted unanimously to keep interest rates at ultralow levels and push ahead with a controversial $600 billion Treasury purchase plan.
Low interest rates have been a boon for noninterest-bearing gold by reducing the opportunity costs of holding the metal.
Another cornerstone of gold's historic rise has been inflation expectations. As a hedge against rising prices, gold has benefited because some don't believe the Fed will be able to sponge up extra liquidity from the low rates and Treasury purchases in time to avoid problematic consumer and producer price increases.
So far, inflation in the U.S. has been tame, but some see it picking up over the longer term.
-By Matt Whittaker, Dow Jones Newswires; 212-416-2139; matt.whittaker@ dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/nae/al?rnd=XIGmskkcqpJAgqfPOcnaVg%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
01-27-110929ET
Copyright (c) 2011 Dow Jones & Company, Inc
LBSR news today,
http://ih.advfn.com/p.php?pid=nmona&article=46190122&symbol=LBSR
LBSR - Daily Candlesticks
And this to go with it
PRECIOUS METALS: Gold Rises Slightly After Data Disappoint 01/27 08:29 AM
NEW YORK (Dow Jones)--Gold futures rose slightly Thursday as weaker-than- forecast U.S. durable goods orders and jobless claims boosted expectations monetary policy will remain easy for longer.
The most actively traded gold contract, for February delivery, was recently up $2.30, or 0.2%, at $1,335.30 a troy ounce on the Comex division of the New York Mercantile Exchange.
"The prospect of low rates being continued here is why (gold) rebounded," said MF Global analyst Tom Pawlicki.
Gold jumped after data showed U.S. demand for long-lasting goods unexpected fell last month, as manufacturers' orders for durable goods decreased 2.5% when economists had predicted a 1.4% gain.
Separate figures showed the number of U.S. workers filing new claims for unemployment benefits unexpectedly surged last week. Initial jobless claims rose 51,000 to 454,000 in the week ended Jan. 22. Economists had expected claims would rise by just 1,000.
The disappointing data reinforced the notion the Federal Reserve will stick to its easy-money policy of ultralow interest rates and Treasury purchases that has helped send gold to record highs in recent weeks.
Federal Reserve officials this week, at their first policy-setting meeting of 2011, voted unanimously to keep interest rates at ultralow levels and push ahead with a controversial $600 billion Treasury purchase plan.
Low interest rates have been a boon for noninterest-bearing gold by reducing the opportunity costs of holding the metal.
Another cornerstone of gold's historic rise has been inflation expectations. As a hedge against rising prices, gold has benefited because some don't believe the Fed will be able to sponge up extra liquidity from the low rates and Treasury purchases in time to avoid problematic consumer and producer price increases.
So far, inflation in the U.S. has been tame, but some see it picking up over the longer term.
-By Matt Whittaker, Dow Jones Newswires; 212-416-2139; matt.whittaker@ dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/nae/al?rnd=XIGmskkcqpJAgqfPOcnaVg%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
01-27-110929ET
Copyright (c) 2011 Dow Jones & Company, Inc
LBSR news today,
http://ih.advfn.com/p.php?pid=nmona&article=46190122&symbol=LBSR
LBSR - Daily Candlesticks
LBSR NEWS! scheduled to return to Abu Dhabi in early February.
http://ih.advfn.com/p.php?pid=nmona&article=46190122&symbol=LBSR
Still digging, this one just turned phantom.... hummm
This is getting fun....
MMTE .0018, what a day!
Unreal buys into the close,imo just getting started...
.0018 MMTE THIS GETTING FUN!@
.0017 this cold get wild!imo
MMTE .0016!!!!!!
Closing @ .0016 would make me very happy imo
Goind to get fun IMO, big buys!
Getting very very wild in here!
Getting hot in here imo... real real hot
Ip must be getting close. imo. lots of new eyes here.
lets hope so
Picked up some @ .039 last week when ask was @ .04 cant beat getting filled under ask.
Waiting is hard indeed, but thats ok....
First Patients Recruited In The Extended Phase III Programme Using Lu AA21004 In MDD
H. Lundbeck A/S (Lundbeck) announced that the first patients have been recruited and dosed in the new phase III programme using Lu AA21004 in major depression (MDD). The first patients have been recruited in Finland. As previously communicated filing of Lu AA21004 is anticipated in 2012. The extended phase III programme for Lu AA21004 is based on clinical data obtained until now. Available data show encouraging results for the potential efficacy and the tolerability profile of Lu AA21004: -- A European based 560-patient placebo-controlled MDD study shows statistical significance on the primary efficacy endpoint across all tested doses. -- Additionally a 639-patient relapse prevention study shows statistical significance in maintenance of efficacy in long-term treatment of MDD. -- Supportive study shows separation from placebo with 5 and 10 mg doses. -- Finally, the proof of concept study (clinical phase II) shows statistical significance on all tested dosesThe phase III programme aims to recruit patients from Europe, as well as the US and Canada in cooperation with our partner Takeda Pharmaceutical Company Limited (Takeda).About Lu AA21004 Lu AA21004 is an investigational multi-modal antidepressant that combines two pharmacological modes of action; reuptake inhibition and receptor activity. Lu AA21004 is a 5-HT3, 5-HT7 and 5-HT1B receptor antagonist, 5 HT1A receptor agonist and 5-HT transporter inhibitor. A number of investigations in vivo have demonstrated that Lu AA21004 increases extracellular monoamine (5-HT, noradrenaline and dopamine) and acetylcholine and histamine levels in specific areas of the brain. All of these activities are considered to be of clinical relevance and potentially involved in the mechanism of action of Lu AA21004.Lu AA21004 has demonstrated a low drug-drug interaction potential. It is extensively metabolized in the liver and the absorption of Lu AA21004 is independent of food intake.About depression Depression is a very common, debilitating illness affecting around 121 million people worldwide according to WHO. Depression was the leading cause of disability as measured by YLD (Years of Life lived with Disability) and the 4th leading contributor to the global burden of disease as measured by DALYs (Disability Adjusted Life Year) in 2000. By the year 2020, depression is projected to reach 2nd place of the ranking of DALYs calculated for all ages, both sexes.The symptoms of depression can be chronic or recurrent, and impact patients both mentally and physically, yet it is still under-recognized and undertreated with less than 25 percent of those affected having access to adequate treatment for their condition[1].Symptoms can include feelings of sadness, anxiety, loss of interest in activities, decreased energy, impaired sleep, impaired concentration, hopelessness, guilt, persistent physical symptoms such as pain and digestive disorders, and in more severe cases, suicidal thoughts and suicide attempts.Takeda and Lundbeck alliance In September 2007, Lundbeck and Takeda formed a strategic alliance for the exclusive co-development and co-commercialization in the United States and Japan of several compounds in Lundbecks pipeline for the treatment of mood and anxiety disorders. The partnership initially focuses on co-development and co-commercialization of the two most advanced compounds in Lundbecks pipeline for mood and anxiety disorders, Lu AA21004 and Lu AA24530. Once approved, the companies will co-promote the products in the United States and Japan. About Lundbeck H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington"s, epilepsies, Alzheimers and Parkinsons diseases.Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and employs today approximately 5,900 people worldwide. Lundbeck is one of the worlds leading pharmaceutical companies working with CNS disorders. In 2009, the companys revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD 2.6 billion). Source: Lundbeck
Oncimmune LLC, builder of EarlyCDT-Lungâ„¢, a elementary red red red red blood exam that aids physicians in risk comment and the early showing of lung cancer, voiced validation examine formula demonstrating the evidence and mercantile benefits of a standardised and reproducible autoantibody laboratory exam (AABT) that competence significantly urge the augury for lung cancer patients. Currently, lung cancer is obliged for some-more deaths than breast, prostate, colon, liver, kidney and cancer cancers combined.(1)Studies were finished with 573 patients well well well known to have lung cancer who were suited opposite normal patients (no lung cancer) for the same age, sex and smoking history. The test, that is regulated underneath CLIA, has 40% attraction and 90% specificity. This equates to that the exam detects 40% of lung cancers, together with early theatre disease (Stages I and II), and the altogether correctness of the exam is larger than 88%. This opening compares agreeably with alternative well well well well known tests such as mammography in younger women or in the box of lung cancer, where EarlyCDT-Lung opening is at slightest twice as great as CT. Study commentary indicate that the autoantibody exam is not shabby by sex, ethnicity, geographic place of patients or the participation of soft autoimmune diseases. Previous studies have shown that autoantibodies can be rescued up to five years prior to tumors can be seen in slight evidence imaging procedures such as CT.(2)Oncimmune researchers additionally set onward the modeled cost-effectiveness of EarlyCDT-Lung as an assist to lung cancer diagnosis, with an estimated $6,000 intensity cost assets for each QALY (quality-adjusted hold up year) saved. Study formula are being introduced in mixed print presentations Jun 6, 2010, at the annual assembly of the American Society of Clinical Oncology."Oncimmunes endless examine has shown that plain tumors can beginner an defence reply ensuing in quantifiable levels of autoantibodies (immuno-biomarkers) that can be rescued in the marginal blood. Ultimately this provides biological report vicious to enabling progressing cancer showing and potentially becoming different the stream model of diagnosis and diagnosis for majority plain tumors together with lung and breast, in between others," pronounced John Robertson, M.D., Professor of Surgery at Nottingham University, England, and Chief Scientific Officer of Oncimmune LTD. According to the American Cancer Society, a lung cancer patients majority appropriate possibility of participation is early detection.(3) EarlyCDT-Lung has the intensity to brand the really early stages of lung cancer when diagnosis can be majority successful."I am tender with the pointing and trustworthiness this exam shows in studies involving hundreds of cancer patients and controls. It has been well well well known for a little time that autoantibodies are supportive early indicators of cancer. EarlyCDT-Lung allows contrast people at high risk for lung cancer in sequence to brand a group who competence already have occult, curable tumors on the basement of a elementary sure result," pronounced William C. Wood, M.D., Professor of Surgery, Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine. In 2009, Oncimmune launched the EarlyCDT-Lung exam to a singular series of office-based physicians in the Midwest and Southeast. Currently, scarcely 500 physicians in some-more than 80 practices suggest EarlyCDT-Lung to exam their high-risk patients. The following investigational presentations simulate Oncimmune-sponsored lung cancer studies presented at this years ASCO Annual Meeting: -- "Use of serum autoantibodies to brand early-stage lung cancer: A poignant step brazen in early detection" Sunday, Jun 6, 2010, 8 a.m - twelve noon, S Hall A2, Poster #19F. Abstract authors: Laura J. Peek, Ph.D., Oncimmune USA LLC; Stephen Lam, British Columbia Cancer Agency; Graham Healey, Oncimmune LTD; Herbert A. Fritsche, Ph.D., UT MD Anderson Cancer Center; Caroline Chapman, Division of Breast Surgery, University of Nottingham; Andrea Murray, Oncimmune LTD; Paul Maddison, University Hospitals NHS Trust; John F. R. Robertson, MD, MBBS, Division of Breast Surgery, University of Nottingham; and William Wood, Emory University School of Medicine. -- "Demographics of populations at high risk of lung cancer and formula of the EarlyCDT-Lungâ„¢ Test" Sunday, Jun 6, 2010, 8 a.m - twelve noon, S Hall A2, Poster #19 G. Abstract authors: John Mathew, MS, FRCS, Division of Breast Surgery, University of Nottingham; Graham Healey, Oncimmune LTD; William Jewell, Oncimmune USA LLC; Andrea Murray, Oncimmune LTD; Caroline Chapman, Division of Breast Surgery, University of Nottingham; Laura J. Peek, Ph.D., Oncimmune USA LLC; Anthony C. Barnes, Ph.D., Rules-Based Medicine; William Wood, Emory University School of Medicine; John F. R. Robertson, MD, MBBS, Division of Breast Surgery, University of Nottingham; and Peter Boyle, International Prevention Research Institute. -- "Cost-effectiveness of an autoantibody exam (AABT) as an assist to diagnosis of lung cancer" Sunday, Jun 6, 2010, 8 a.m - twelve noon, S Hall A2, Poster #19D. Abstract authors: Derek Weycker, Ph.D., Policy Analysis, Inc. (PAI); James R. Jett, M.D., Medical Oncology, Mayo Clinic; Frank C. Detterbeck, MD, Yale School of Medicine; Daniel L. Miller, MD, Emory University School of Medicine; Anne Khuu, Policy Analysis, Inc. (PAI); Timothy C. Kennedy, University of Colorado Denver, Cancer Center; Peter Boyle, International Prevention Research Institute; John F. R. Robertson, MD, MBBS, Division of Breast Surgery, University of Nottingham; Geoffrey Hamilton-Fairley, Oncimmune LTD; and John Edelsberg, MD, MPH, Policy Analysis, Inc. (PAI). About Early Immuno-BiomarkersEarly immuno-biomarkers, in the form of autoantibodies, are constructed in reply to the participation of sure by-products from cancer cells (i.e., proteins called antigens). When the physique recognizes something as "non-self" one of the ways it responds is for the defence complement to furnish large amounts of antibodies. The defence complement does not routinely furnish antibodies opposite normal tissue antigens and thus these immuno-biomarkers to cancer antigens yield high specificity for cancer. Tests that acknowledge autoantibodies to a singular growth protein have been accessible for a series of years but have had low pickup rates (sensitivity). Previously, mixed antigen tests had low specificity, generally for early detection. Oncimmunes EarlyCDT-Lung exam has increasing the attraction of the autoantibody exam whilst progressing a high turn of specificity.About Oncimmune EarlyCDT-LungOncimmunes EarlyCDT-Lung exam uses a row of growth antigens to acknowledge the participation of immuno-biomarkers constructed in the form of autoantibodies by the patients defence system. Elevation of any one of 6 immuno-biomarkers (autoantibodies) on top of a fixed cutoff worth suggests that a growth competence be present. This elementary red red red red blood exam aids in risk comment and the early showing of lung cancer in high-risk asymptomatic studious populations. The key value of the exam is the capability to acknowledge cancer earlier, and with higher specificity, than spiral-CT that is the customary evidence imaging exam used for these patients today. EarlyCDT-Lung is labelled next a CT indicate and as a elementary red red red red blood test, eliminates deviation bearing from imaging screening techniques. High-risk people such as long-term smokers and ex-smokers in between the ages of 40 and 75 and people with alternative risk factors such as environmental exposures and endless bearing to delegate fume are possibilities for the test. Further examine to examine the majority profitable clinical have use of the exam (i.e., as a initial exam heading to serve contrast for those positive, or as a exam on condition that serve report to those who already have a CT identified nodule) is now being finalized. EarlyCDT-Lung is CLIA (Clinical Laboratory Improvement Act) regulated. Other tests for breast, ovarian, esophagogastric, colon and liver cancers are planned. About Oncimmune LLCOncimmune (USA) LLC, founded in 2006, is an industry personality in early cancer detection. The association is committed to some-more advanced early cancer showing by exclusive immuno-biomarker technologies formed on biological record identified by John Robertson, M.D., Professor of Surgery at Nottingham University, England, and Chief Scientific Officer of Oncimmune LTD. Ongoing examine and growth is conducted by Oncimmune underneath the citation of Professor Robertson. The companys mission is to rise early cancer showing tests to brand some-more than 90% of solid-tumor cancers, that have up 70% of all cancers together with lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. All contrast is achieved to one side inside of Oncimmunes CLIA-registered laboratory located in De Soto, Kansas, in the metro Kansas City area. Oncimmune LLC is a unconditionally owned auxiliary of Oncimmune LTD. Oncimmune LTD owns a portfolio of patents, together with Patent Nos. 7,402,403 and 7,205,117, with five others now filed and underneath review. (1) http://www.lungcancerfoundation.org/about-lung-cancer/fact-sheets(2) Zhong L, Coe SP, Stromberg AJ, et al.: Profiling tumor-associated antibodies for early showing of non-small cell lung cancer. J Thor Oncol 1:513 - 519, 2006.(3) American Cancer Society.Source: Oncimmune LLCThe infancy of Australians (58%) are disturbed about their brain health and the hazard of age-related degenerative brain disease, according to a new survey.The inhabitant consult was commissioned by heading healing investigate hospital Neuroscience Research Australia and polled 1000 Australians elderly eighteen to over 75."More and some-more Australians are witnessing the debilitating goods of brain diseases similar to dementia," pronounced Professor Peter Schofield, Executive Director of Neuroscience Research Australia."In the survey, roughly 70% of people pronounced they knew someone influenced by a brain disease, damage or illness. Despite this open concern, the new 2010-11 bill was wordless on appropriation investigate that will correct and even forestall these diseases."Of those surveyed, comparison baby boomers were the majority anxious, with roughly 70% disturbed about their brain health. More than half pronounced they would be peaceful to put off early retirement to keep their mind active and healthy. More than half of immature adults surveyed additionally fright dementia, Alzheimers or TU Delft and Molecular Imaging Labs (MI Labs) have succeeded in mixing dual forms of healing imaging techniques in to one square of equipment. These techniques are quite utilitarian for cancer research. The dual techniques are well well known as microPET and microSPECT. SPECT and PET can be achieved concurrently and they give a higher fortitude than normal microSPECT and microPET. The new device is well well known as the VECTor (Versatile Emission Computed Tomography) and is written for make make use of in elemental investigate in to the functioning of cells and organs. It can show organic sum not as big than half a millimetre.Cancer researchPositron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) are used in cancer investigate and diagnosis, between alternative things. PET and SPECT are additionally ordinarily used to lift out elemental investigate in to vital cells and disease mechanisms or to rise improved methods of diagnosis and treatment. The equipment that has right away been grown at TU Delft and MI Labs is written for elemental investigate utilizing initial animal models. The total PET/SPECT equipment offers intensely high resolution, reduces make make use of of laboratory animals and additionally offers monetary assets when carrying out investigate in this area. Previously, both sorts of equipment would have had to be paid for alone and less report could be gained from each particular animal.Unprecedented precisionProf. Freek Beekman, highbrow at TU Delft and CEO/CSO of MI Labs, formerly was in assign of building the U-SPECT, one of the dual elements in the new total apparatus. This U-SPECT (Ultra-high fortitude Single Photon Emission Computed Tomographer) is most some-more accurate than the normal SPECT equipment or alternative scanning techniques."These scanners concede us to see how cells and viscera duty in rare detail. There are already some-more than ten U-SPECTs around the globe, that can exam new tracers and pharmaceuticals for cancer, cardiac problems and brain diseases," says Beekman.Early detectionThe U-SPECT, and after the total U-SPECT/PET scanner, is right away being used for investigate utilizing mice. "The plea is right away to set up a U-SPECT that can be used on people, so that tumours can be rescued and personal early, for example, and the right diagnosis can be proposed immediately," says Beekman.Medical DeltaThe serve growth of U-SPECT is piece of the worldwide query for some-more fit healing imaging technology, radiotherapy and swelling seekers. These efforts are solemnly but certainly heading to ever improved cancer treatments, according to Beekman. We still have most to benefit by mending record for detecting and treating cancer. Beekman emphasises that it is critical for hospitals and technicians to work together really closely.TU Delft and MILabs are receiving movement in this area by participating in Medical Delta. They are auxiliary with Erasmus University, the University of Leiden and their dual dependent educational hospitals.Source: Ilona outpost basement BrinkDelft University of Technology
are you following this, just noticed it on my crawl. if so hit me up for dd, if not I am sorry to bother you and will have this deleted. pm me if you need anything
http://www.google.com/#q=hdvy&hl=en&tbo=1&output=search&source=lnt&tbs=qdr:d&sa=X&ei=uTI2TdjxE4_EsAPB3s3pAQ&ved=0CAUQpwUoAg&fp=4ef1ed213f96a03d
Looks like we have lots of eyes look @ us...
still following this one.... waiting for a q to disappear hope it does sooon imo
This is why I wake up every morning....
Wolv: SS o/s per 10q 105 million....
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7658237
DD on the way...
pending news...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58072728
Another sleeper IMO (DD too) they have spread like wild fire.
http://www.otcmarkets.com/stock/NLEF/company-info
Market Value1 $12,028,806 a/o Jan 13, 2011
Shares Outstanding 75,180,038 a/o Nov 11, 2010
Float N/A
Authorized Shares 500,000,000 a/o Dec 31, 2007
Par Value 0.001
More DD picks coming soon. very soon. HDVY keep an eye out
funny stuff @ the wolv board
This is a Link to YOUR post correct?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58808832
Here is a link to 10q: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7658237
The filing before that was the 8-k :
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7535269
Message in reply to:
To much worry about the little downward pressure on miniscule volume...Like I said before folks will be continually assessing their risk and lost opportunities elsewhere while waiting for a single point success of failure event...So expect daily shavings...If we do get anticipation buying with significant volume it is because there is a leak somewhere...but at least the news will be good...opposite on high volume is true as well..
[/quote]
Induced polarization is expected soon from my research. If you believe that I am incorrect in anything I post, please provide links that are not to your own posts.
Can you please provide links to support this claim?